A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

By Deming Dustin   Ninan Jacob   Bailey Howard   Kolesar Jill   Eickhoff Jens   Reid Joel   Ames Matthew   McGovern Renee   Alberti Dona   Marnocha Rebecca   Espinoza-Delgado Igor   Wright John   Wilding George   Schelman William  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 323-329

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies

By Sayar H.   Shen Z.   Lee S.   Royce M.   Rabinowitz I.   Lee F.   Smith H.   Eberhardt S.   Maestas A.   Lu H.   Verschraegen C.  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 153-158

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx^®) in combination with topotecan in patients with advanced malignancies

By Ghesquières Hervé   Faivre Sandrine   Djafari Latifa   Pautier Patricia   Lhommé Catherine   Lozahic Stéphanie   Djazouli Kamel   Armand Jean-Pierre   Raymond Eric  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 413-421

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

By Argiris Athanassios  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1575-1584

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

By Deenen Maarten  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1557-1565

Springer Publishing Company

Access to resources Recommend Favorite